drugset / Trial / NCT03607188
Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
To explore the DLT of ZG0418 for Patients with Advanced ALK+ or ROS1+ NSCLC And Previously Treated with Chemotherapy or Crizotinib, and to determine the MTD or the R2PD.
Timeline
- Start
- 2018-10-18
- Primary completion
- 2022-10-17
- Completion
- 2022-10-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alkotinib | Unknown | 200 mg | Oral |
| Subject | Alkotinib | Unknown | 300 mg | Oral |
| Subject | Alkotinib | Unknown | 400 mg | Oral |
| Subject | Alkotinib | Unknown | 500 mg | Oral |
| Subject | Alkotinib | Unknown | 600 mg | Oral |